Mesoblast Ltd (MESO) stock
MESONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends June 30Also trades as MEOBF
$13.27+0.17 (+1.30%)
Close on Nov 13, 2026Market cap $1.72BP/E –Yield –
Mesoblast r&d expenses
Research and development expenses are spending on new products and technology.
Mesoblast's R&D Expenses for the twelve months ending Jun 30, 2023 was $52.82M, up 61.0% year over year. For fiscal 2026 it was $97.51M, up 180.1% from the year before. Over ten years it grew 6.9% a year on average. The highest annual figure on record is $97.51M in fiscal 2026.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | $97.51M | +180.1% |
| FY2025 | Jun 30, 2025 | $34.81M | -12.4% |
| FY2024 | Jun 30, 2024 | $39.72M | -24.8% |
| FY2023 | Jun 30, 2023 | $52.82M | +61.0% |
| FY2022 | Jun 30, 2022 | $32.82M | -38.1% |
| FY2021 | Jun 30, 2021 | $53.01M | -5.7% |
| FY2020 | Jun 30, 2020 | $56.19M | -6.1% |
| FY2019 | Jun 30, 2019 | $59.82M | -9.3% |
| FY2018 | Jun 30, 2018 | $65.93M | +11.9% |
| FY2017 | Jun 30, 2017 | $58.91M | +17.8% |
| FY2016 | Jun 30, 2016 | $50.01M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2023CQ2 2023 | Jun 30, 2023 | $32.32M | +541.4% |
| Q3 FY2023CQ1 2023 | Mar 31, 2023 | $7.07M | -14.4% |
| Q2 FY2023CQ4 2022 | Dec 31, 2022 | $7.68M | -24.7% |
| Q1 FY2023CQ3 2022 | Sep 30, 2022 | $5.74M | -38.4% |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | $5.04M | -28.6% |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | $8.25M | -33.7% |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | $10.20M | -28.4% |
| Q1 FY2022CQ3 2021 | Sep 30, 2021 | $9.33M | -51.6% |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | $7.06M | -53.8% |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | $12.44M | -13.5% |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | $14.24M | +0.6% |
| Q1 FY2021CQ3 2020 | Sep 30, 2020 | $19.28M | +55.6% |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | $15.27M | +33.5% |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | $14.38M | -0.2% |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | $14.15M | -8.6% |
| Q1 FY2020CQ3 2019 | Sep 30, 2019 | $12.39M | -33.0% |
| Q4 FY2019CQ2 2019 | Jun 30, 2019 | $11.44M | -34.8% |
| Q3 FY2019CQ1 2019 | Mar 31, 2019 | $14.41M | -14.2% |
| Q2 FY2019CQ4 2018 | Dec 31, 2018 | $15.49M | -4.5% |
| Q1 FY2019CQ3 2018 | Sep 30, 2018 | $18.49M | – |
| Q4 FY2018CQ2 2018 | Jun 30, 2018 | $17.54M | – |
| Q3 FY2018CQ1 2018 | Mar 31, 2018 | $16.80M | – |
| Q2 FY2018CQ4 2017 | Dec 31, 2017 | $16.22M | – |
See a number that looks wrong?